AstraZeneca has just announced positive Breast cancer results from a head to head Phase III trial which compares its PARP inhibitor, called Lynparza versus physician’s choice chemotherapy in 1st- to 3rd-line germline BRCA mutation positive metastatic breast cancer patients.
Results showed a statistically significant and clinically meaningful improvement in progression free survival compared with those who received chemotherapy.
These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways.
After a disappointing readout of Abbvie’s Phase II BROCADE trial of their PARP, AstraZeneca could now be the first company to make available its PARP inhibitor to breast cancer patients.